Evidence map›Paper›PMID 38153687›Full record

ReviewCurrent treatment options in oncology2023

Research Progress on the Cardiotoxicity of EGFR-TKIs in Non-Small Cell Lung Cancer.

Yinan Yu, Jianguo Zhao, Jiaona Xu, Rui Bai, Zewei Gu, Xialin Chen, Jianfang Wang, Xueying Jin, Gaoyang Gu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Yinan Yu *Department of Oncology, Shaoxing People's Hospital, Shaoxing, Zhejiang Province, China.ORCID 0000-0001-7984-6970
Jianguo Zhao *Department of Oncology, Shaoxing People's Hospital, Shaoxing, Zhejiang Province, China.
Jiaona Xu *Department of Rehabilitation, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
Rui BaiDepartment of Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
Zewei GuSchool of Clinical Medicine, Hangzhou Medical College, Hangzhou, Zhejiang Province, China.
Xialin ChenDepartment of Oncology, Shaoxing People's Hospital, Shaoxing, Zhejiang Province, China.
Jianfang WangDepartment of Oncology, Shaoxing People's Hospital, Shaoxing, Zhejiang Province, China.
Xueying JinDepartment of Oncology, Shaoxing People's Hospital, Shaoxing, Zhejiang Province, China.
Gaoyang GuDepartment of Cardiology, the First People's Hospital of Huzhou, 158 Plaza Back Road, Wuxing District, , Huzhou, 313000, Zhejiang Province, China. gugaoyang1005@163.com.
Shaoxing People's Hospital · CNHangzhou First People's Hospital · CNHangzhou Medical College · CNSecond Affiliated Hospital of Zhejiang University · CNThird People's Hospital of Huzhou · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementWith the development of molecular biology and histology techniques, targeted therapy for non-small cell lung cancer (NSCLC) has emerged, which is highly effective and has marginal side effects. Epidermal growth factor receptor (EGFR) was the first driver gene discovered, whose three generations of therapeutic use have its characteristics and benefits in clinical practice. However, cardiovascular complications by EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in preclinical studies have been increasingly reported, including heart failure, cardiomyopathy, and QT prolongation, among others. Cardiotoxicity of targeted drugs significantly affects the therapeutic effect of NSCLC and has become the second leading cause of death in NSCLC. The aim of the present review was to recognize the potential cardiotoxicity of third-generation targeted drugs in the treatment of NSCLC and their associated mechanisms to help clinicians identify and prevent it early in the treatment, minimize the cardiotoxicity of targeted drugs, and improve the therapeutic effect of patients.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsCardiotoxicityErbB ReceptorsHumansMutationProtein Kinase InhibitorsEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsCardiotoxicityEpidermal growth factor receptorNon-small cell lung cancerTyrosine kinase inhibitor

Identifiers

PMID38153687
OpenAlexW4390345530

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.